What happened?
Shares of medical device company Globus Medical (NYSE: GMED) fell 11.6% in the afternoon session after the company reported third-quarter 2026 revenue below Wall Street's estimates and lowered its full-year revenue guidance.
According to a company press release, Globus Medical reported revenue of $763.7 million for the third quarter ended September 30, 2026, which was flat year on year. Revenue was below Wall Street's estimate of $792.4 million. Adjusted earnings per share was $1.23, which was above Wall Street's estimate of $1.20. The company lowered its full-year revenue guidance to $3.09 billion at the midpoint from $3.20 billion, while reiterating its full-year adjusted earnings per share guidance of $5.00 at the midpoint. The updated revenue guidance was 3.4% below analyst estimates.
Management stated that the performance reflected timing delays for product launches in U.S. Spine alongside delayed revenue recovery at Nevro following its 2025 restructuring. The company also disclosed that its board of directors authorized an additional $500 million for its share repurchase program.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Globus Medical? Access our full analysis report here, it’s free.
What is the market telling us
Globus Medical’s shares are somewhat volatile and have had 10 moves greater than 5% over the last year. But moves this big are rare even for Globus Medical and indicate this news significantly impacted the market’s perception of the business.
The previous big move we wrote about was 2 days ago when the stock gained 9.4% on the news that election results confirmed that Democrats reclaimed majorities in the House and Senate, easing regulatory uncertainty around drug pricing policy.
As reported by CNBC, Wall Street analysts project that the biopharmaceutical sector's recovery will strengthen in the wake of the congressional election outcome. Investors had feared potential disruptions to healthcare policies, but analysts noted that drug pricing legislation is unlikely to dominate the new legislative agenda. Prior statutory frameworks already established expanding annual Medicare price negotiations, meaning existing government policies will remain intact without unexpected new restrictions. Furthermore, broader equity markets and index futures rebounded as investors interpreted the shifting balance of power in Washington as a stabilizing dynamic.
The presence of congressional checks and balances is widely viewed by market strategists as a moderating force on executive policy decisions, creating a predictable regulatory climate that supports ongoing investments across pharmaceutical and biotechnology developers.
Globus Medical is down 17.7% since the beginning of the year, and at $71.88 per share, it is trading 25.8% below its 52-week high of $96.82 from April 2026. Investors who bought $1,000 worth of Globus Medical’s shares 5 years ago would now be looking at only $927.06.
WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.
This is what the early days of Palantir looked like before it became a giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.
